Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in Upcoming Investor Events
September 03, 2024 08:00 ET | Compass Therapeutics
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
August 12, 2024 08:00 ET | Compass Therapeutics
Compass Therapeutics announces 2nd quarter results and provides clinical results update
Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 07, 2024 08:00 ET | Compass Therapeutics
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass-logo-RGB-outlines.png
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
August 06, 2024 08:00 ET | Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET | Compass Therapeutics
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces CEO Transition
May 28, 2024 16:10 ET | Compass Therapeutics
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
May 23, 2024 17:05 ET | Compass Therapeutics
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 14, 2024 08:00 ET | Compass Therapeutics
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET | Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Compass-logo-RGB-outlines.png
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
April 25, 2024 08:00 ET | Compass Therapeutics
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study...